EC approves Regeneron’s immunotherapy for cervical cancer
Pharmaceutical Technology
NOVEMBER 23, 2022
Libtayo is also indicated for treating progression of the disease on or following platinum-based chemotherapy. Based on the open-label, multicentre, international Phase III EMPOWER-Cervical 1 clinical trial findings, the regulatory agency granted approval in advanced cervical cancer.
Let's personalize your content